<DOC>
	<DOCNO>NCT02717884</DOCNO>
	<brief_summary>The objective phase I part trial determination maximum tolerate dose ( MTD ) TCP ( Tranylcypromine ) combination fixed-dose ATRA ( all-trans-retinoic acid ) fixed-dose AraC ( Cytarabine ) derive recommend phase II dose ( RP2D ) patient non-APL AML MDS standard treatment available fail azanucleoside treatment . The objective phase II part trial first evaluation efficacy TCP RP2D combination fixed-dose ATRA fixed-dose AraC basis investigation TCP</brief_summary>
	<brief_title>Study Sensitization Non-M3 AML Blasts ATRA Epigenetic Treatment With Tranylcypromine ( TCP )</brief_title>
	<detailed_description>Study treatment : TCP + ATRA + AraC Four dose level TCP ( 20 mg , 40 mg , 60 mg , 80 mg day 1-28 ) examine combination fix dose ATRA ( 45 mg/m2 day 10-28 ) fixed-dose AraC ( 40 mg day 1-10 ) first cycle . In cycle patient treat manner , except ATRA administer continuously nine-day interruption begin every fourth cycle . Follow-up per patient : Until twelve month registration last patient . Duration intervention per patient : Until relapse/progression , unacceptable toxicity twelve month registration last patient , whatever occur first</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Tranylcypromine</mesh_term>
	<criteria>Patients eligible inclusion trial must meet following criterion : 1 . Patients &gt; 18 year ( upper age limit ) ; 2 . AML ( WHO ) intermediate high risk MDS/ Chronic Myelomonocytic Leukemia ( CMML ) ( IPSSR &gt; 3.0 ) ; 3 . No standard treatment available ( comorbidities , high age , refractoriness standard salvage chemotherapy allografting , azanucleosides failure* ) ; 4 . Patients &lt; 30.000 leukocytes/Âµl ; 5 . Eastern Cooperative Oncology Group ( ECOG ) 0,1,2 ; 6 . Written inform consent obtain accord international guideline local law ; 7 . Ability understand nature trial trial related procedure comply . Azanucleosides failure define 1 ) response least three ( AML ) six ( MDS ) cycle azacitidine decitabine , 2 ) disease progression treatment 3 ) grade 34 nonhematologic toxicity . Patients eligible trial must meet following criterion : 1 . Acute promyelocytic leukemia ( APL , FrenchAmericanBritish classification system ( FAB ) M3 ) ; 2 . Eligibility standard induction consolidation chemotherapy , immediate allografting , hypomethylating agent ; 3 . AML central nervous system ( CNS ) involvement ; 4 . AraC treatment within one month prior registration ; 5 . Prior exposure histone deacetylase inhibitor , include sodium valproate within one month prior registration ; 6 . Stem cell transplant patient graftversushost disease ( GvHD ) systemic immunosuppression ; 7 . Previous gastrointestinal surgery might interfere drug absorption ; 8 . Pheochromocytoma ; 9 . Carcinoid tumor ; 10 . Confirmed suspected cerebrovascular disease ; 11 . Vascular malformation include aneurysm ; 12 . Severe renal insufficiency ; 13 . Severe poorly control hypertension ; 14 . Severe cardiovascular disease ; 15 . Hepatic insufficiency/liver disease ; 16 . Porphyria ; 17 . Diabetes insipidus ; 18 . History presence malignant hyperthermia ; 19 . Known psychiatric disorder ; 20 . Known allergy soy bean peanuts ; 21 . Known hypersensitivity intolerance one trial drug constituent ( e.g . lactose , corn starch , indigocarmine ( TCP ) , corn starch ( AraC ) , retinoids ( ATRA ) ) ; 22 . Simultaneous intake prohibit medication , incl . linezolid , likely cause interaction ( see detailed list study protocol ) ; 23 . Patients refuse follow studyspecific dietary guideline ; 24 . Known persistent abuse medication , drug alcohol ; 25 . Current planned pregnancy , nursing period ; 26 . Failure use safe method contraception ; 27 . Simultaneous participation interventional trial could interfere trial and/or participation end require restriction period ; 28 . Participation clinical trial within last 30 day start trial 29 . Persons relationship dependence/employment sponsor investigator ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>relapse</keyword>
	<keyword>trans-retinoic acid ATRA</keyword>
	<keyword>epigenetic treatment</keyword>
	<keyword>non-M3 AML blast</keyword>
	<keyword>tranylcypromine TCP</keyword>
	<keyword>LSD1</keyword>
	<keyword>refractory</keyword>
</DOC>